Novavax
NVAX
234 hedge funds and large institutions have $826M invested in Novavax in 2024 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 80 increasing their positions, 54 reducing their positions, and 41 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
48% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 54
5.53% more ownership
Funds ownership: 58.6% → 64.13% (+5.5%)
0% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 41
1% less funds holding
Funds holding: 237 → 234 (-3)
29% less call options, than puts
Call options by funds: $65.9M | Put options by funds: $92.9M
30% less capital invested
Capital invested by funds: $1.19B → $826M (-$361M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$41.7M |
| 2 |
Morgan Stanley
New York
|
+$32.7M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$19.3M |
| 4 |
SCM
Shah Capital Management
Raleigh,
North Carolina
|
+$12.9M |
| 5 |
BlackRock
New York
|
+$8.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Coatue Management
New York
|
-$28.1M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$23.5M |
| 3 |
Two Sigma Advisers
New York
|
-$11.8M |
| 4 |
Jane Street
New York
|
-$8.55M |
| 5 |
Millennium Management
New York
|
-$7.63M |
NVAX Hedge Fund Activity: Q4 2024 in Review
234 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q4 2024, worth a combined $826M — down 30% from $1.19B a quarter earlier.
Fund positioning in NVAX was balanced in Q4 2024: 41 funds opened new positions, 41 closed out, 80 added to existing stakes and 54 trimmed.
The largest buyer was UBS Group, adding an estimated $41.7M. The largest seller was Coatue Management, exiting entirely with an estimated $28.1M sold.
- 234 institutional investors held Novavax (NVAX) as of Q4 2024, down from 237 in Q3 2024.
- Funds reported $826M of Novavax stock for Q4 2024, down 30% quarter-over-quarter.
- 41 funds opened new Novavax positions in Q4 2024 and 41 closed out, a net change of 0 holders.
- The largest Novavax buyer in Q4 2024 was UBS Group, an estimated $41.7M added.
- The largest Novavax seller in Q4 2024 was Coatue Management, an estimated $28.1M sold.
Based on aggregated 13F filings for Q4 2024.